drugset
Drugs / mericitabine
last change Jan 2016 re-read 9 days ago

mericitabine

also known as RO5024048 · 3',5'-DIISOBUTYRYL PSI 6130 · Mericitabina · PSI 6130 DIISOBUTYRATE · R 7128 · RG 7128 · Ro5024048; r7128

Small molecule

Developed for
chronic hepatitis C virus infection · hepatitis C virus infection
Investigated by
Hoffmann-La Roche · Pharmasset

Trials 12

today NCT01628094 · Ph 2 NCT01483742 · Ph 2 NCT01482403 · Ph 2 NCT01331850 · Ph 2 NCT01278134 · Ph 2 NCT01152671 · Ph 1 NCT01099904 · Ph 1 NCT01057667 · Ph 2 NCT00801255 · Ph 1 NCT00382798 · Ph 1/2 NCT00377182 · Ph 2 NCT00869661 · Ph 2
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT01152671 Jun → Aug 2010 — Hoffmann-La Roche Completed No outcome recorded
Phase 1 NCT01099904 Mar → Sep 2010 — Hoffmann-La Roche Completed No outcome recorded
Phase 1 NCT00801255 Nov 2008 → Mar 2010 chronic hepatitis C virus infection Hoffmann-La Roche Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00382798 Oct 2006 → Sep 2008 hepatitis C virus infection Pharmasset Completed No outcome recorded
Phase 28 trials
Phase 2 NCT01628094 Jun 2012 → Nov 2013 chronic hepatitis C virus infection Hoffmann-La Roche Completed No outcome recorded
Phase 2 NCT01483742 Apr 2012 → Sep 2013 chronic hepatitis C virus infection Hoffmann-La Roche Completed No outcome recorded
Phase 2 NCT01482403 Nov 2011 → Jan 2014 chronic hepatitis C virus infection Hoffmann-La Roche Completed No outcome recorded
Phase 2 NCT01331850 May 2011 → Jan 2013 chronic hepatitis C virus infection Hoffmann-La Roche Completed No outcome recorded
Phase 2 NCT01278134 Feb 2011 → Oct 2012 chronic hepatitis C virus infection Hoffmann-La Roche Completed No outcome recorded
Phase 2 NCT01057667 Feb 2010 → Apr 2012 chronic hepatitis C virus infection Hoffmann-La Roche Completed No outcome recorded
Phase 2 NCT00377182 Sep 2006 → Aug 2008 chronic hepatitis C virus infection Hoffmann-La Roche Completed No outcome recorded
Phase 2 NCT00869661 Feb 2001 → Feb 2012 chronic hepatitis C virus infection Hoffmann-La Roche Completed No outcome recorded
Comparator or background therapy1 trial
Phase 2 NCT01579019 Comparator Jul 2012 → Mar 2014 chronic hepatitis C virus infection Hoffmann-La Roche Withdrawn No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 15 sources stand behind the page.

FieldValueCited text
Known as mericitabine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01482403 ↗
Known as 3',5'-DIISOBUTYRYL PSI 6130 ChEMBL registry synonym — accepted as the source's own label CHEMBL562967 ↗
Known as Mericitabina ChEMBL registry synonym — accepted as the source's own label CHEMBL562967 ↗
Known as PSI 6130 DIISOBUTYRATE ChEMBL registry synonym — accepted as the source's own label CHEMBL562967 ↗
Known as R 7128 ChEMBL registry synonym — accepted as the source's own label CHEMBL562967 ↗
Known as RG 7128 ChEMBL registry synonym — accepted as the source's own label CHEMBL562967 ↗
Known as RO5024048 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01331850 ↗
11

NCT00377182 ↗

NCT01278134 ↗

NCT01579019 ↗

NCT01057667 ↗

NCT01152671 ↗

NCT00801255 ↗

NCT01099904 ↗

NCT00382798 ↗

NCT00869661 ↗

NCT01628094 ↗

Show 1 more source
Known as Ro5024048; r7128 ChEMBL registry synonym — accepted as the source's own label CHEMBL562967 ↗
Action Inhibit “HCV polymerase inhibitor pro-drug” NCT00377182 ↗
Modality Small molecule “mericitabine (nucleoside analog inhibitor of HCV polymerase)” PMID 26752189 ↗ Jan 2016
1

CHEMBL562967 ↗
Route Oral “1500mg po bid for 4 weeks” NCT00377182 ↗